Retreatment With Intratumoral Diffusing Alpha Radiation Emitters

Inclusion Criteria: * Subjects with histopathological confirmation of either recurrent or persistent disease following DaRT treatment. * Subjects with a tumor size ≤ 5 centimeters in the longest diameter. * Target lesion technically amenable for full coverage with the Alpha DaRT seeds. * Brachytherapy indication validated by a multidisciplinary team. * Measurable disease according to RECIST v1.1. * Subjects over 18 years old. * Subjects' ECOG Performance Status Scale is \< 2. * Subjects' life expectancy is more than 6 months. * Platelet count ≥100,000/mm3. * AST and ALT ≤ 2.5 X ULN * WBC ≥ 3500/μl, granulocyte ≥ 1500/μl * International normalized ratio of prothrombin time ≤1.4 for patients not on Warfarin * Creatinine ≤2.3 mg/dL. * Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy. * Subjects are willing to sign an informed consent form. Exclusion Criteria: * Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids * Known hypersensitivity to any of the components of the treatment. * Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in…